Space Pharmaceuticals appoints Dr. Marco Pickel as Director of Business Development

We are pleased to welcome Dr. Marco Pickel as Director of Business Development. With decades of API industry experience in top leading companies in the pharmaceutical, cosmetics, food, adhesives and coatings fields, Dr. Pickel will play a key role in the development of Space Peptides CDMO business.

Opening ceremony celebrates the construction for Space Peptides, a Space Pharmaceuticals company, of a large-scale peptide manufacturing facility in Jiangsu, China

Space Peptides, a Space Pharmaceuticals company, will invest approximately USD 150 million to build state-of-the-art manufacturing facilities, expanding to an annual capacity of 1100 kg to support scaling of peptide active pharmaceutical ingredient production to clinical and commercial manufacturing, covering therapeutic areas of women’s health, metabolic diseases, antimicrobial and onco-immunology.

The new facility will have an area of approximately 80,000 square meter, with the latest manufacturing technology. Construction of the manufacturing facility is expected to finish in Dec 2022, whereas the plant is expected to be fully operational in 2023.

“The investment is supported by a strong market demand, strong pipeline and underlines Space Peptides’ continuing commitment to serving the peptide pharmaceutical market across scales”, says Dr. Runze He, CEO of Space Pharmaceuticals.

Space Peptides, a Space Pharmaceuticals company, completes GMP-like inspection by China’s National Medical Products Administration (NMPA, previously called CFDA)

Space Peptides, a Space Pharmaceuticals company, successfully completes the GMP inspection carried out by China’s regulatory agency National Medical Products Administration (NMPA, previously called CFDA). The comprehensive inspection covered the Space Peptides Xiamen facility’s quality processes and entire production system., which meets the requirements for producing peptide intermediates / advanced intermediates and active pharmaceutical ingredients (APIs) for clinical trial phase I and II. Currently, a pipeline of peptide therapeutic products with GMP / GMP-like standards are being manufactured at the site.

This demonstrates the company’s premier quality system in full compliance with regulatory requirements.

Dr. Runze He, CEO of Space Pharmaceuticals, commented, “We are excited to successfully complete the regulatory inspection. We will continue to be dedicated to the highest quality standards and, ultimately, patient safety”

Space Peptides, a Space Pharmaceuticals company, announces its new in vitro / in vivo testing laboratory at the Xiamen Science Park in China

“With our new in vitro / in vivo testing laboratory closely connected with the peptide production site, Space Pharmaceuticals provides integrated peptide drug discovery from computational prediction, peptide synthesis and laboratory testing results, forming close iterative cycles”, said Dr. Runze He, CEO at Space Pharmaceuticals.

“Operational this month, the testing facility at Xiamen National Science Park, China, is a cornerstone for our peptide discovery partnerships, enabling the most efficient and effective discovery process combining our GDBspace drug discovery engine with on-demand high-quality peptide production and experimental data generation for feedback loops”, said Dr. Jingwen Shi, Chief Business Officer at Space Pharmaceuticals, responsible for the company’s drug discovery partnerships.